The deal calls for Murata, which makes ceramic capacitors and already owned a 3% stake in Vios, to offer more than 500,000 stock shares worth roughly $75.7 million plus $25.8 million in cash, according to the Nikkei Asian Review.
The system is in use at hospitals in India and the U.S., where it won 510(k) clearance from the FDA in December 2015, on a trial basis. St. Paul, Minn.-based Vios Medical plans for a full-scale launch in the next several years, according to the review.
Vios posted net losses of -$1.9 million last year, according to the report.
For its part Murata wants to augment its existing medical equipment business and integrate its sensor and telecommunications technologies into the Vios system, the Nikkei review reported.